+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid reduces hepatic allograft rejection after orthotopic liver transplantation A prospective, randomized, placebo-controlled, double-blind trial



Ursodeoxycholic acid reduces hepatic allograft rejection after orthotopic liver transplantation A prospective, randomized, placebo-controlled, double-blind trial



Hepatology 22(4 Part 2): 149A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144889

Download citation: RISBibTeXText


Related references

Treatment with ursodeoxycholic acid does not prevent acute rejection after liver transplantation A prospective randomized, placebo-controlled double-blind Nordic multicentre study. Journal of Hepatology 23(Suppl. 1): 85, 1995

A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection. Liver Transplantation and Surgery 4(4): 276-279, 1998

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease A double-blind, randomized, placebo-controlled trial. Hepatology 36(4 Part 2): 412A, 2002

Tranexamic acid reduces blood loss after primary shoulder arthroplasty: a double-blind, placebo-controlled, prospective, randomized controlled trial. Jses Open Access 2(1): 23-27, 2019

The effect of octreotide on urine output during orthotopic liver transplantation and early postoperative renal function; a randomized, double-blind, placebo-controlled trial. Hepatitis Monthly 13(9): E12787, 2013

A randomized double-blind trial of prophylactic ursodeoxycholic acid vs placebo to prevent veno-occlusive disease of the liver in patients undergoing allogeneic bone marrow transplantation. Blood 84(10 Suppl. 1): 250A, 1994

A prospective randomized double-blind trial evaluating the efficacy of ursodeoxycholic acid in preventing acute rejection. Hepatology 24(4 Part 2): 177A, 1996

Effect of ursodeoxycholic acid in facilitating early hepatic clearance of radiotracer among patients undergoing 99mTc-sestamibi myocardial perfusion scintigraphy: A randomized double blind placebo controlled parallel trial. Journal of Nuclear Cardiology 2019, 2019

A Randomized, Double-Blind, Placebo-Controlled Trial of Ursodeoxycholic Acid in Primary Biliary Cirrhosis. Hepatology. 22(3): 759-766, 1995

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 144(4): 239-248, 2006

The effects of ursodeoxycholic acid therapy in biliary atresia A double blind, randomized, placebo controlled trial. Pediatric Research 33(4 Part 2): 97A, 1993

Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. Journal of the American College of Cardiology 59(6): 585-592, 2012

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52(2): 472-479, 2010

Randomized double-blind trial of ursodeoxycholic acid vs placebo for total parenteral nutrition-associated liver dysfunction. Journal of Hepatology 21(Suppl. 1): S148, 1994

Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transplantation 7(9): 802-807, 2001